Orexigen Therapeutics posts $175,000 December operating loss, no sales

By Caroline Salls

Pittsburgh, Jan. 30 – Orexigen Therapeutics, Inc. reported a $175,000 loss from operations for December on zero net product sales, according to its monthly operating report filed Wednesday with the U.S. Bankruptcy Court for the District of Delaware.

In comparison, Orexigen posted a $239,000 loss from operations for November, also on zero net product sales.

The net gain for December was $771,000, improving over a $981,000 November net loss.

The company had $26.93 million in cash and cash equivalents as of Dec. 31, down from $27.95 million at the end of November.

Orexigen is a San Diego-based biopharmaceutical company focused on the treatment of obesity. The company filed for bankruptcy on March 12, 2018 under Chapter 11 case number 18-10518.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.